NL-OMON51069已完成不适用
PET imaging of the noradrenaline system in different neurodegenerative conditions - JPND HEROES
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •all participants:
- •age between 50 - 80 years
- •Healthy volunteers:
- •Willingness to cooperate and sign written informed consent.
- •Participants with Alzheimer's disease:
- •Diagnosis of AD according to the criteria from the National Institute on
- •Aging-Alzheimer*s Association (NIA-AA)
- •Willingness to cooperate and sign written informed consent.
- •MMSE score between 18-26 (inclusive);
- •Participants with Parkinson's disease
- •Willingness to cooperate and sign written informed consent.
- •Diagnosis of PD according to the London Parkinson*s disease society brain
- •Participants with Parkinson's disease and dementia:
- •Willingness to cooperate and sign written informed consent.
- •Diagnosis of PD according to the London Parkinson*s disease society brain
- •MMSE score between 18-26 (inclusive);
- •Participants with Down Syndrome:
- •availability of a caregiver/proxy who will be present at visits.
- •Participants with Downsyndrome & dementia
- •availability of a caregiver/proxy who will be present at visits.
- •A Clinical diagnosis of AD based on the Dementia Scale for Down Syndrome
- •(Gedye A., 1995. Dementia Scale for Down Syndrome. Vancouver, BC: Gedye
- •Research and Consulting) and on the Behavioral and Pyschological Symptoms of
- •Dementia in Down Syndrome (BPSD-DS) scale (Dekker A.D. et al., 2018) developed
- •by our group and recently optimized (in press, Dekker A.D. et al., 2021).
排除标准
- •All participants:
- •usage of any medication that affects the noradrenaline system
- •Contra-indications for MRI or PET (such as claustrophobia)
- •brain MRI evidence of any structural abnormality, such as major stroke or
- •mass that is likely to interfere with the interpretation of the PET scan;
- •Past or present developmental disorder or psychiatric disorder (expect for
- •Down's syndrom)
- •Healthy volunteers:
- •Abnormal results on the Mini-Mental State Examination (MMSE) (<27);
- •(Subjective) memory complaints;
- •Absence of signed informed consent form
- •Participants with Alzheimer's Disease:
- •History of neurological conditions other than AD;
- •Absence of signed informed consent form
- •Participants with Parkinson's disease
- •History of neurological conditions other than PD;
- •Absence of signed informed consent form
- •Past or present developmental disorder or psychiatric disorder
- •Participants with Parkinson's disease and dementia:
- •History of neurological conditions other than PD-D;
- •Absence of signed informed consent form.
- •Participants with Down's Syndrome:
- •Absence of signed informed consent form or of caretaker/study partner (proxy
- •consent and assent).
- •Participants with Down's syndrome & dementia
- •Absence of signed informed consent form or of caretaker/study partner (proxy
- •consent and assent).
研究者
相似试验
已完成
不适用
PET imaging of the noradrenaline system in healthy volunteers - a pilot studyNL-OMON48264niversitair Medisch Centrum Groningen4
尚未招募
不适用
PET imaging of the noradrenaline system in healthy volunteers - a pilot studyPilot study: healthy volunteers only.NL-OMON21724niversity Medical Center Groningen4
进行中（未招募）
1 期
orepinephrine transporter PET imaging in neural crest and neuroendocrine tumors using a new fluorine-18 based norepinephrine transporter tracer (18F-MFBG): a phase I PET/CT studyEUCTR2019-003872-37-BEniversity Hospitals Leuven10
已完成
早期 1 期
The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose TissueBrown Adipose TissueNCT02038595Yale University10
进行中（未招募）
不适用
PET imaging of neuroendocrine tumoursEUCTR2012-002513-19-SEKarolinska University Hospital Solna